• Twitter
  • Facebook
  • LinkedIn
Biweekly newsletter of the International Cytokine & Interferon Society

Biweekly newsletter of the International Cytokine & Interferon Society

Signals+ Editors: Daniella Schwartz & Di Yu (Editors in Chief), Saurabh Chattopadhyay, Zhian Chen, Mohamed Saad & Maialen Sebastian-delaCruz
  • Subscribe
  • Archives
    • Archives (Oct. 2023 and before)
      • Signals+ October 2022 PDF
      • Signals+ April 2021 PDF
      • Signals+ April 2022 PDF
  • Awards
  • Annual Meeting
  • Member News
    • Member Highlights
    • Members in the News
    • Members on the Move
    • New Member Mini-Bios
    • Articles of Interest
    • Reviews of Interest
  • Society News
    • President’s Letter
    • Featured Article!
  • Industry News
    • Industry Partner News
    • Other Meetings
    • Clinical Trials
HomeSignals+ PDFPast Issue PDFsSignals+ April 2021 PDF

Signals+ April 2021 PDF

April 12, 2021 Past Issue PDFs

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Previous

Signals+ Archive from October 2020 – the Inaugural Issue in 1994

Next

A NOTE FROM THE OUTGOING PRESIDENT, Kate Fitzgerald:

Banner Image of ICIS President, Sarah Gaffen
Featured Article!

Presidents Message: What the Cytokines Meeting Means to Me

May 5, 2025

If you only attend one conference this year… here’s why it should be Cytokines-2025! Just Right Ever since I attended my first Cytokines conference (Amsterdam, 2000), this meeting has been THE event on my scientific calendar. I admit to being a little biased, but I think Cytokines conferences are perfect [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Person on high peak overlooking the ocean
Member Highlights

Member Highlight: Meet Deanna Santer, Ph.D.

May 5, 2025

My lab is passionate about human interferons and especially type III interferons where there is still a lot to learn about! We are interested in how interferons regulate immune responses. However, when I’m not in the lab I like playing sports and hanging out with my family. Scientist should not [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)

May 4, 2025

ClinicalTrials.gov ID NCT05941845 Sponsor Centre Hospitalier Universitaire de Nice Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party) Study Overview – Brief Summary Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

May 4, 2025

ClinicalTrials.gov ID NCT05870475 Sponsor Institute of Hematology & Blood Diseases Hospital, China Information provided by Institute of Hematology & Blood Diseases Hospital, China (Responsible Party) Study Overview – Brief Summary Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)

May 4, 2025

ClinicalTrials.gov ID NCT05843786 Sponsor Hospices Civils de Lyon Information provided by Hospices Civils de Lyon (Responsible Party) Study Overview – Brief Summary Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy

Go to mobile version